title: Different subtypes of carcinoma in situ of the bladder do not have a different prognosis.
abstract: Urothelial carcinoma in situ (CIS) is a high-grade lesion with different subtypes (large cell pleomorphic (LCP), large cell nonpleomorphic (LC), small cell and clinging (CL)). We explored the frequency of different subtypes in primary CIS and compared different patterns with outcome. We explored whether subtyping of CIS leads to a change in therapy and/or follow-up and should be formally reported. We included 39 patients with a primary CIS and divided them into two groups: one with LPC/LG and one with CL elements. Other subtypes did not exist or occurred only as a mixture. Patient age ranged from 36 to 80 years (mean, 63 years). Twenty had a primary CIS with one single subtype. LCP was predominant with 16 (41 %) cases; the second most important subtype was the CL with four (10 %) cases. Mean follow-up was 26.4 months, (range, 4-100 months). Thirteen patients developed a ≥ pT2 carcinoma. When progression of the different subtypes was examined, no statistical significance was found between mixed forms (p = 0.9437) nor between pure forms (p = 0.744 and p = 0.5955, respectively). Pathologists need not include different subtypes of primary CIS in their report as there is no difference in patient outcomes. It is important to recognize all different subtypes as CIS for best patient treatment.
authors: Department of Pathology, Hôpital La Pitié-Salpétrière, Assistance-Publique Hôpitaux de Paris, Université Pierre et Marie Curie University Paris VI, 47-83, Bd de l'Hôpital, 75013 Paris, France. ecomperat@yahoo.fr
authors: Eva
authors: E
authors: Compérat
authors: Solene-Florence
authors: SF
authors: Jacquet
authors: Justine
authors: J
authors: Varinot
authors: Pierre
authors: P
authors: Conort
authors: Morgan
authors: M
authors: Roupret
authors: Emmanuel
authors: E
authors: Chartier-Kastler
authors: Marc-Olivier
authors: MO
authors: Bitker
authors: Johannes Alfred
authors: JA
authors: Witjes
authors: Olivier
authors: O
authors: Cussenot
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002278:Carcinoma in Situ / Q000401:mortality / Q000473:pathology*; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology*
references: Int J Surg Pathol. 2009 Apr;17(2):99-106
references: 19019843
references: Cancer. 1999 Jun 1;85(11):2469-74
references: 10357420
references: Virchows Arch. 2001 Oct;439(4):552-9
references: 11710643
references: Eur Urol. 2009 Sep;56(3):430-42
references: 19576682
references: Eur Urol. 2004 Feb;45(2):142-6
references: 14733997
references: J Urol. 1952 Jul;68(1):261-79
references: 14939458
references: Scand J Urol Nephrol. 2011 Dec;45(6):411-8
references: 21793636
references: Am J Surg Pathol. 2001 Mar;25(3):356-62
references: 11224606
references: BJU Int. 2003 Dec;92(9):906-10
references: 14632844
references: J Urol. 2003 Apr;169(4):1541-5
references: 12629411
references: Hum Pathol. 2011 Dec;42(12):1923-30
references: 21683985
references: J Urol. 1992 Jan;147(1):11-5
references: 1729494
references: J Urol. 1994 Aug;152(2 Pt 1):388-92
references: 8015077